Collectively, our study suggests that these distinct changes of BTLA and HVEM expressions on circulating CD4+ and CD8+ T cell contribute to immunosuppressive state of HCC patients and may serve as attractive targets for HCC immunotherapy. The gene discussed is TNFRSF14; the disease is hepatocellular carcinoma.